GRAIL is trading at $71.88 (4.3% up) as the stock rebounds from recent losses despite a lack of company-specific catalysts.

  • The upward move follows a 5.11% drop on July 20, with no new earnings updates or regulatory events appearing in available news.
  • The price action is consistent with a bounce in a volatile name amid higher broader markets, even as the biotech sector provides a mixed backdrop.